Summary of Conference Call Records Industry Overview - The focus is on the innovative drug sector, particularly in the context of recent significant transactions and developments in the PD(L)1*VEGF and GLP1 fields [1][2]. Key Points and Arguments PD(L)1*VEGF Dual Antibody Developments - 康方生物 and Summit announced top-line data from the global clinical trial HARMONI for Ivosidenib targeting 2L EGFRm, indicating: - The PD(L)1*VEGF dual antibody shows certain effectiveness in the post-EGFRm mutation line, although the median follow-up time is short, necessitating longer follow-up for evaluation [1] - The HARMONI study validates the consistency of clinical results between China and the U.S. [1] - The FDA stated that statistically significant overall survival benefits are necessary to support the submission for market approval, which will influence Summit's timeline for BLA submission [1] - The primary focus remains on the first-line global clinical results for Ivosidenib [1] Collaboration and Licensing Opportunities - BMS and BNTX are collaborating on the development of PD(L)1*VEGF dual antibodies, with BMS committing to: - An upfront payment of $1.5 billion, $2 billion in non-contingent annual payments, potential milestone payments of $7.6 billion, and a 50:50 cost/profit sharing arrangement [2] - The continuous licensing of PD(L)1*VEGF assets reflects MNCs' optimism regarding these types of drugs, suggesting potential for identifying advantageous subpopulations for clinical benefits [2] - Other companies such as ROG and ABBV are also expected to have demand for similar assets, with domestic firms like 荣昌生物, 宜明昂科, 华海药业, 华兰生物, and 神州细胞 making strategic moves in this area [2] GLP1/GIP Dual Agonist Transactions - Regeneron and Hansoh Pharmaceutical reached a deal for the GLP1/GIP dual agonist, with Regeneron paying an upfront fee of $80 million, $1.93 billion in milestones, and a double-digit sales share [2] - The past year has seen ABBV, REGN, and JNJ entering the diabetes and weight loss market, expanding competition against existing players like LLY, NVO, MSD, ROG, and AZN [2] - The ongoing interest from MNCs in the weight loss sector is expected to lead to a resurgence of new drug developments, particularly following data releases from conferences like ADA [2] Recommended Companies - The following companies are recommended for attention: - 恒瑞医药, 华东医药, 联邦制药, 歌礼制药, 来凯医药 [3] Market Trends - There is optimism regarding the Chinese innovative drug sector due to ongoing licensing activities, which are expected to drive a bullish market trend [4] - MNCs have reiterated their interest in Chinese assets during recent earnings calls, reflecting a strong demand for domestic innovative drugs and low policy sensitivity [4] - The continuous licensing of Chinese innovative drugs is anticipated to lead to a revaluation of overseas valuations [4] - Recommended stocks for Pharma revaluation include 恒瑞医药, 华东医药, 三生制药, 联邦制药, 中国生物制药, 石药集团/新诺威, 先声药业, 康哲药业, 科伦药业; for Biotech global competitiveness: 益方生物, 泽璟制药, 一品红, 百利天恒, 科伦博泰生物, 贝达药业, 信达生物, 百济神州, 再鼎医药, 和黄医药 [4]

| 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 猪肉 | 2.39 | 可控核聚变 | -3.47 | | 养鸡 | 1.94 | 减速器 | -3.18 | | 创新药 | 1.56 | EDR概念 | -3.01 | | 动物疫苗 | 1.35 | 人形机器人 | -2.90 | | 眼科医疗 | 1.30 | 一体化压铸 | -2.79 | | 细胞免疫治疗 | 1.25 | 汽车热管理 | -2.63 | | 青蒿素 | 1.17 | 无线充电 | -2.51 | | 仿制药一致性评价 | 1.16 | 铜缆高速连接 | -2.49 | | 重组蛋白 | 1.11 | 拼多多概念 | -2.48 | | 生物疫苗 | 1.01 | 智能座舱 | -2.48 | 资金面上看，今日重组蛋白概念板块获主力资金净流出1.72亿元，其中，15股获主力资金净流入，5股 主力资金净流入超千万元，净流入资金居首的是热景生物，今日主力资金净流入5560.70万元，净流入 资金居前的还有皓元医药、睿智医药、贝达药业等，主力资金分别净流入4228. ...

Group 1 - The cell immunotherapy concept index rose by 1.25%, ranking 6th among concept sectors, with 29 stocks increasing in value [1][2] - Notable gainers included Ruizhi Pharmaceutical with a 20% limit up, Hainan Haiyao at limit up, and Shutaishen, Guanhao Biological, and Fosun Pharma with increases of 15.02%, 8.88%, and 5.23% respectively [1][6] - The sector experienced a net outflow of 266 million yuan, with 20 stocks seeing net inflows, and 8 stocks receiving over 10 million yuan in net inflows, led by Hainan Haiyao with a net inflow of 144 million yuan [2][3] Group 2 - Hainan Haiyao, Anke Bio, and Dongcheng Pharmaceutical had the highest net inflow ratios at 35.56%, 5.52%, and 5.27% respectively [3][4] - The top stocks by net inflow included Hainan Haiyao, Fosun Pharma, Ruizhi Pharmaceutical, and Zhaoyan New Drug, with net inflows of 144 million yuan, 54.52 million yuan, 34.78 million yuan, and 31.86 million yuan respectively [2][3] - Stocks with significant declines included Xue Rong Biological, Saifutian, and Jinchang Protein, with decreases of 4.23%, 2.74%, and 2.61% respectively [1][5]

Core Viewpoint - The article emphasizes the importance of collaboration between financial capital and industrial capital to foster the development of technology-driven industries, highlighting the need for a sustainable investment model that supports long-term economic growth and innovation [1][2]. Group 1: Financial Capital and Industrial Collaboration - Participants at the conference discussed the necessity for patient capital to build a matrix that supports the development of technology-oriented industries, creating a strong capital engine to inject continuous momentum into new productive forces [2]. - Wu Guoyuan, Chairman of Zhejiang Bank Wealth Management, stated that wealth management institutions should focus on creating a sustainable "common prosperity" asset management model, converting scattered resident funds into long-term capital to support the construction of common prosperity demonstration zones [4]. - Nanhua Futures General Manager Jia Xiaolong highlighted the role of China's futures market in serving the real economy and managing risks, emphasizing the increasing demand for overseas hedging as commodity and foreign trade grow [4]. Group 2: Case Studies in Innovation and Investment - Fan Jianxun, Vice President of Betta Pharmaceuticals, shared insights on the G-CVC model (Government-Industry Capital Venture) that the company employs to create an innovative ecosystem, managing four industry funds totaling 3 billion yuan, with successful investments in oncology and autoimmune diseases [5]. - Chen Mian, founding partner of Dian Shi Capital, discussed the firm’s long-term commitment to hard technology investments, focusing on semiconductors, chips, and artificial intelligence, and how this strategy has gained recognition over the past decade [6]. - The article notes that Betta Pharmaceuticals has seen three companies go public during the "capital winter," with expectations of 8 to 10 new drug launches in the next two years, benefiting humanity [5].

Market Overview - The A-share market continued to show a sideways consolidation trend, with the Shanghai Composite Index closing at 3340.69 points, down 0.18%, and the Shenzhen Component Index at 10029.11 points, down 0.61% [1] - The total trading volume of the Shanghai and Shenzhen markets was 998.9 billion yuan, ending a streak of 23 consecutive trading days with over 1 trillion yuan in trading volume [1] Food and Beverage Sector - The food and beverage sector showed resilience, with the Shenwan Food and Beverage Index closing up 0.17%. Notably, yellow wine stocks performed exceptionally well, with Kuaijishan and Jin Feng Wine Industry hitting the daily limit, and Guyue Longshan rising over 7% [2] - The China Alcoholic Drinks Association noted that as living standards rise, consumer demand for alcoholic products is becoming more diverse and personalized, particularly for yellow wine, which is recognized for its health benefits and unique taste [2] - The consumption of yellow wine is expected to expand, moving beyond traditional settings to include daily drinking, leisure gatherings, and business banquets, thus becoming a significant part of consumers' daily lives [2] - National Bureau of Statistics data indicated that in April, national catering revenue reached 416.7 billion yuan, a year-on-year increase of 5.2%, providing strong support for stable growth in the consumer market [2] Innovative Pharmaceuticals Sector - The pharmaceutical sector is experiencing a bottom recovery, with innovative drugs showing sustained activity. Notably, Sangamo Therapeutics saw its stock price hit a 20% limit up, closing up 15.31%, with a cumulative increase of 115% over the past seven trading days [3] - On May 20, Sangamo announced a deal with Pfizer, granting exclusive rights for the global development, production, and commercialization of its self-developed PD-1/VEGF bispecific antibody SSGJ-707, excluding the Chinese market, for a record upfront payment of 1.25 billion USD [3] - Analysts believe that this record-setting upfront payment highlights the competitive advantages and market potential of domestic innovative drugs, suggesting a positive cycle of "frontier innovation—commercialization—reinvestment in R&D" for the industry [3] Consumer Sector Trends - The A-share consumer sector is showing signs of rotation, with new consumption areas such as pet consumption and IP economy gaining traction. However, some institutions express concerns about overheating in certain new consumption segments [4] - Recent statistics indicate that leading new consumption companies, such as Pop Mart and Laopu Gold, have shown strong performance, driving market sentiment towards new consumption directions [4] - The beauty and pet food indices have seen their trading volume relative to the entire A-share market reach historical highs, indicating potential overheating in short-term trading indicators [4]

第八届（2025）西湖大会举行当天正值小满节气。主办方设置了以节气命名的特色对话环节——小满茶 座。来自金融资本、产业资本和实体产业的相关负责人，以实践为基石、以融合为导向，展开了一场资 本与产业协同发展的探讨。与会人士指出，各方耐心资本应携手共同构建金融助力科技型产业发展的矩 阵，打造资本强引擎，为新质生产力发展持续注入动能。 范建勋透露，公司目前管理4只产业基金，规模达30亿元，在肿瘤、自身免疫疾病等领域，以及细胞治 疗和CAT-T等前沿性领域均有布局和投资，并取得了良好成果与回报。 "尽管基金运作时间不长，但在前几年'资本寒冬'情况下，我们在生物医药领域已有3家公司上市，实现 了部分退出。"范建勋说，"从社会价值角度看，未来两年，预计有8个至10个新药上市，造福人类。" 如何扩大创新的生态圈、朋友圈？范建勋这样复盘：一是依托贝达药业完整的产业链，涵盖研发、临 床、产业化、商业化等环节；二是建立"两个翅膀"，除规模30亿元的产业基金外，还有"梦工厂"孵化 器，已吸引近300个项目进行孵化与投资，同时引进了300多位高端人才；三是在G—CVC运营中，围绕 产业、前沿科学和临床需求，打造战略布局、协同、延伸和 ...

Group 1 - The core viewpoint is that the pharmaceutical sector is gradually recovering, reflected in the performance of listed companies, despite limited overall index growth [1] - The manager emphasizes a balanced approach to investment, focusing on risk-reward ratios and aiming for excess returns relative to the pharmaceutical index over time [1] - The fund manager has a strong track record, with the fund achieving a return of 87.60% since inception, ranking first in its category for various time frames [1] Group 2 - The fund's investment scope includes various segments of the pharmaceutical and healthcare industry, such as chemical pharmaceuticals, traditional Chinese medicine, biological products, and medical services [2] - The top ten holdings of the fund are diversified across high-growth areas like innovative drugs and medical devices, which helps mitigate individual stock volatility while participating in overall industry growth [2] - The holdings are balanced, reducing the risk associated with any single stock and enhancing exposure to the sector's growth potential [2]

中国经济网北京5月27日讯 20日，智通财经发布《名单炸裂？64位基金经理近三年跑输基准超10%，还 有百亿老将在列》一文。文中称，据济安金信统计，截至今年4月30日，市场上有64位基金经理旗下全 部基金的近三年年化收益率均跑输基准超10%（各类份额合并计算，且仅统计成立满三年的产品）。其 中，广发基金郑澄然、摩根士丹利基金王大鹏、信达澳亚基金邹运共有4只基金管理时长超三年，且4只 基金的近三年年化收益率均跑输基准10%。 从摩根士丹利基金王大鹏目前正在管理的基金来看，包括大摩沪港深精选混合A/C、大摩健康产业混合 A/C、大摩消费领航混合、大摩卓越成长混合，且时间最短3年，最长超过8年。 但在任职回报上，大摩沪港深精选混合A/C与大摩健康产业混合C，均遭遇大幅下跌，值得注意的是这 两只基金的起始管理时间均在2021年内，且重仓股均以医药股为主。今年一季报显示，大摩沪港深精选 混合的前十大重仓股为科伦博泰生、药明康德（603259）、恒瑞医药（600276）、泽璟制药、信达生 物、百济神州、康诺亚、康龙化成（300759）、贝达药业（300558）、昭衍新药（603127）。大摩健康 产业混合C的前十大重仓股 ...

Core Viewpoint - The A-shares market experienced a slight decline on May 27, with the Shanghai Composite Index closing at 3340.69 points, down 0.18%. The A500 Index ETF (159351) also saw a minor adjustment, closing down 0.62% [1]. Group 1: Market Performance - The A500 Index ETF (159351) had an active trading day with a total transaction volume of 2.466 billion yuan, ranking second among similar products in the market and first in the Shenzhen market [1]. - The turnover rate of the A500 Index ETF reached 17.07%, the highest among similar products with a scale of over 10 billion yuan [1]. - Despite the market's fluctuations, the A500 Index ETF attracted over 300 million yuan in net inflows over the past four trading days [1]. Group 2: Component Stocks - Notable stocks that performed well include Penghui Energy, which hit the daily limit, and Beida Pharmaceutical, China Great Wall, and Junshi Biosciences, all of which rose over 7% [1]. Group 3: Valuation and Investment Potential - The current price-to-book ratio (PB) of the CSI A500 Index is 1.46, which is considered low historically [1]. - The overall PEG ratio of the new productivity-related component stocks is at 0.9, significantly lower than the 1.2 of the Nasdaq Golden Dragon Index, indicating strong long-term investment value [1]. Group 4: Investment Tools - The A500 Index ETF (159351) tracks the CSI A500 Index, consisting of 500 large-cap and liquid stocks across various industries, providing a balanced investment tool for A-share representative companies [2]. - Investors can also access the A500 Index ETF through linked funds (Class A 022453; Class C 022454) to capitalize on quality core asset opportunities [2].

Core Viewpoint - The pharmaceutical sector, particularly innovative drugs, is experiencing a significant surge, driven by upcoming events and favorable policies [2][5][9] Group 1: Innovative Drug Market Performance - Innovative drugs have seen substantial gains, with companies like Junshi Bioscience rising over 16% and the Hong Kong market's innovative drug sector increasing nearly 4% [2][4] - The upcoming ASCO conference in Chicago, scheduled for May 30 to June 3, 2025, is expected to further ignite interest in innovative drugs, with numerous Chinese pharmaceutical companies showcasing their research [5][9] Group 2: Clinical Advancements - Junshi Bioscience's JS015 and other drugs are leading in clinical trials, with promising early data indicating a 100% objective response rate (ORR) in certain treatment groups [4] - The 2025 ASCO conference will present updated data, which may enhance the visibility and credibility of Chinese innovative drugs on the global stage [5][9] Group 3: Policy and Market Dynamics - Recent policies, such as the draft action plan for Traditional Chinese Medicine (TCM) in Shanghai, aim to enhance the development and integration of TCM, indicating a supportive environment for the pharmaceutical sector [5] - Long-term investment strategies are focusing on two main areas: international expansion of innovative drugs and recovery of domestic demand, particularly in TCM and consumer healthcare [8][9]